Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
- D. de Zeeuw, T. Akizawa, +17 authors G. Chertow
- The New England journal of medicine
- 25 December 2013
Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of end-stage renal disease (ESRD) or death from cardiovascular causes and was terminated on the recommendation of the independent data and safety monitoring committee. Expand
Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl
The totality of the evidence suggests that through modulation of the endothelin pathway, bardoxolone methyl may pharmacologically promote acute sodium and volume retention and increase blood pressure in patients with more advanced CKD. Expand
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Bardoxolone methyl contributed to events related to heart failure and/or fluid overload in a subpopulation of susceptible patients with an increased risk for heart failure at baseline. Expand
Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)
- D. de Zeeuw, T. Akizawa, +16 authors G. Chertow
- American Journal of Nephrology
- 28 February 2013
The BEACON trial will be the first event-driven trial to evaluate the effect of an oral antioxidant and anti-inflammatory drug in advanced CKD, and potentially reduce renal and cardiac morbidity and mortality. Expand
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney…
Bardoxolone methyl preserves kidney function and may delay the onset of ESRD in patients with T2D and stage 4 CKD and is compared with placebo on a post-hoc composite renal endpoint. Expand
Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.
- M. Chin, Chun-Yue I. Lee, +5 authors C. Meyer
- American journal of physiology. Renal physiology
- 15 June 2013
The present results are consistent with the overall published body of data obtained with triterpenoids and provide further evidence that these molecules are well tolerated without adverse effects on hepatobiliary or renal function in rodent models of diabetes and obesity. Expand
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
- D. Lynch, J. Farmer, +18 authors C. Meyer
- Annals of clinical and translational neurology
- 10 November 2018
The dose‐ranging portion of this Phase 2 study assessed the safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia patients. Expand
Prediction of nitric oxide concentrations in colonic crypts during inflammation.
Estimates of NO concentrations in inflamed crypts should facilitate efforts to elucidate the molecular biological linkage between NO exposure and carcinogenesis in IBD. Expand
Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations
Sputum density of P. aeruginosa was not increased at the time of CF exacerbation and was not influenced by the presence of viral infection. Expand
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
- James H. Lewis, M. Jadoul, +9 authors G. Chertow
- Clinical and translational science
- 29 August 2020
The data suggest that the increases in ALT and AST observed clinically were, at least in part, related to the pharmacological induction of aminotransferases via Nrf2 activation, rather than to any intrinsic form of hepatotoxicity. Expand